Young-Il Koh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Young-Il Koh has a total of 306 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Hee Choi
Department of Pulmonology and Allergy Hallym University Dongtan Sacred Heart Hospital Hwaseong Korea
11 shared publications - Joo-Hee Kim
Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea
10 shared publications - Min-Hye Kim
Department of Internal Medicine Ewha Womans University College of Medicine Seoul Korea
10 shared publications - Min-Suk Yang
Department of Internal Medicine Seoul Metropolitan Government‐Seoul National University Boramae Medical Center Seoul Korea
9 shared publications - Sang Pyo Lee
Division of Respiratory Disease and Allergy, Department of Internal Medicine Dankook University College of Medicine Cheonan Republic of Korea
9 shared publications - So-Young Park
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Seoul, Korea
9 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Confirmed Multiple Drug Hypersensitivity Syndrome is Uncommon, and its Culprit Drug Spectrum Reflects Patterns of Drug Exposure
Multiple drug hypersensitivity syndrome (MDHS) is defined as confirmed hypersensitivity to two or more chemically and pharmacologically unrelated drug entities. Few studies have characterized MDHS with systematic diagnostic confirmation. We aimed to determine the frequency, culprit drug patterns, and diagnostic findings of confirmed MDHS. We retrospectively reviewed patients evaluated for suspected drug hypersensitivity at a Korean tertiary allergy center from March 2017 to April 2026. MDHS required confirmed hypersensitivity to at least two unrelated drug entities by skin testing, serum‐specific IgE, or provocation testing; cross‐reactive reactions were not counted separately. Among 6684 evaluated patients, 3007 underwent diagnostic testing, and 1380 were tested for multiple suspected drugs. MDHS was confirmed in 94 patients (1.4%, 3.1%, and 6.8%, respectively). Anaphylaxis was the most common manifestation (38.3%). Most patients (84.0%) reacted to two entities, whereas 12.8% and 3.2% reacted to three and four entities, respectively. Leading culprits were β‐lactams ( n = 34), nonsteroidal anti‐inflammatory drugs (NSAIDs)/acetaminophen ( n = 34), antituberculosis agents ( n = 27), and histamine‐2 receptor antagonists ( n = 19). Recurrent combinations involved first‐line antituberculosis agents and NSAIDs plus ranitidine. Of 114 entities confirmed by drug provocation, 38 had negative preceding skin tests. Delayed‐reading intradermal testing was more frequently positive in drug reaction with eosinophilia and systemic symptoms (DRESS) than in maculopapular exanthema (MPE) (53.3% vs. 0.0%, P = 0.008). Confirmed MDHS was uncommon despite suspected hypersensitivity to multiple drugs. The clinical presentation resembled European cohorts, whereas the culprit spectrum reflected regional prescribing patterns. Systematically evaluating each suspected entity may preserve future treatment options.
- 10 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessConfirmed Multiple Drug Hypersensitivity Syndrome is Uncommon, and its Culprit Drug Spectrum Reflects Patterns of Drug Exposure
Multiple drug hypersensitivity syndrome (MDHS) is defined as confirmed hypersensitivity to two or more chemically and pharmacologically unrelated drug entities. Few studies have characterized MDHS with systematic diagnostic confirmation. We aimed to determine the frequency, culprit drug patterns, and diagnostic findings of confirmed MDHS. We retrospectively reviewed patients evaluated for suspected drug hypersensitivity at a Korean tertiary allergy center from March 2017 to April 2026. MDHS required confirmed hypersensitivity to at least two unrelated drug entities by skin testing, serum‐specific IgE, or provocation testing; cross‐reactive reactions were not counted separately. Among 6684 evaluated patients, 3007 underwent diagnostic testing, and 1380 were tested for multiple suspected drugs. MDHS was confirmed in 94 patients (1.4%, 3.1%, and 6.8%, respectively). Anaphylaxis was the most common manifestation (38.3%). Most patients (84.0%) reacted to two entities, whereas 12.8% and 3.2% reacted to three and four entities, respectively. Leading culprits were β‐lactams ( n = 34), nonsteroidal anti‐inflammatory drugs (NSAIDs)/acetaminophen ( n = 34), antituberculosis agents ( n = 27), and histamine‐2 receptor antagonists ( n = 19). Recurrent combinations involved first‐line antituberculosis agents and NSAIDs plus ranitidine. Of 114 entities confirmed by drug provocation, 38 had negative preceding skin tests. Delayed‐reading intradermal testing was more frequently positive in drug reaction with eosinophilia and systemic symptoms (DRESS) than in maculopapular exanthema (MPE) (53.3% vs. 0.0%, P = 0.008). Confirmed MDHS was uncommon despite suspected hypersensitivity to multiple drugs. The clinical presentation resembled European cohorts, whereas the culprit spectrum reflected regional prescribing patterns. Systematically evaluating each suspected entity may preserve future treatment options.
- Open Access
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (3) , 384-393
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Park SY, et al. Allergy Asthma Immunol Res. 2025 May;17(3):384-393. https://doi.org/10.4168/aair.2025.17.3.384
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (3) , 384-393
Open AccessReal-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Park SY, et al. Allergy Asthma Immunol Res. 2025 May;17(3):384-393. https://doi.org/10.4168/aair.2025.17.3.384
- Open Access
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (2) , 271-284
Changes of Clinical Practice Patterns of Allergen Immunotherapy in Korea
Lee HY, et al. Allergy Asthma Immunol Res. 2025 Mar;17(2):271-284. https://doi.org/10.4168/aair.2025.17.2.271
- 1 January 2025
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 17 (2) , 271-284
Open AccessChanges of Clinical Practice Patterns of Allergen Immunotherapy in Korea
Lee HY, et al. Allergy Asthma Immunol Res. 2025 Mar;17(2):271-284. https://doi.org/10.4168/aair.2025.17.2.271
- 16 March 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 225, 107598
Relationship of computed tomography-based measurements with symptom perception and quality of life in patients with severe asthma
- 16 March 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 225, 107598
Relationship of computed tomography-based measurements with symptom perception and quality of life in patients with severe asthma
- Open Access
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (3) , 253-266
Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR
Park SY, et al. Allergy Asthma Immunol Res. 2024 May;16(3):253-266. https://doi.org/10.4168/aair.2024.16.3.253
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (3) , 253-266
Open AccessReal-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR
Park SY, et al. Allergy Asthma Immunol Res. 2024 May;16(3):253-266. https://doi.org/10.4168/aair.2024.16.3.253
- Open Access
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (3) , 267-278
Characteristics of Severe Asthma in the Elderly: Observations From the Korean Severe Asthma Registry (KoSAR)
Lee HY, et al. Allergy Asthma Immunol Res. 2024 May;16(3):267-278. https://doi.org/10.4168/aair.2024.16.3.267
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (3) , 267-278
Open AccessCharacteristics of Severe Asthma in the Elderly: Observations From the Korean Severe Asthma Registry (KoSAR)
Lee HY, et al. Allergy Asthma Immunol Res. 2024 May;16(3):267-278. https://doi.org/10.4168/aair.2024.16.3.267
- Open Access
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (1) , 9-21
The KAAACI Guidelines for Sublingual Immunotherapy
Min JY, et al. Allergy Asthma Immunol Res. 2024 Jan;16(1):9-21. https://doi.org/10.4168/aair.2024.16.1.9
- 1 January 2024
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 16 (1) , 9-21
Open AccessThe KAAACI Guidelines for Sublingual Immunotherapy
Min JY, et al. Allergy Asthma Immunol Res. 2024 Jan;16(1):9-21. https://doi.org/10.4168/aair.2024.16.1.9
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (6) , 725-756
KAAACI Guidelines for Allergen Immunotherapy
Lee HY, et al. Allergy Asthma Immunol Res. 2023 Nov;15(6):725-756. https://doi.org/10.4168/aair.2023.15.6.725
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (6) , 725-756
Open AccessKAAACI Guidelines for Allergen Immunotherapy
Lee HY, et al. Allergy Asthma Immunol Res. 2023 Nov;15(6):725-756. https://doi.org/10.4168/aair.2023.15.6.725
- Open Access
- 1 January 2023
- Published by XMLink in Allergy Asthma & Respiratory Disease
- Vol. 11 (4) , 193-201
Clinical features of patients with paucigranulocytic asthma classified based on the induced sputum test
심다운, et al. Allergy Asthma Respir Dis. 2023 Oct;11(4):193-201. https://doi.org/10.4168/aard.2023.11.4.193
- 1 January 2023
- Published by XMLink in Allergy Asthma & Respiratory Disease
- Vol. 11 (4) , 193-201
Open AccessClinical features of patients with paucigranulocytic asthma classified based on the induced sputum test
심다운, et al. Allergy Asthma Respir Dis. 2023 Oct;11(4):193-201. https://doi.org/10.4168/aard.2023.11.4.193
- Open Access
- 30 September 2022
- Published by Korean Society for Pharmacoepidemiology and Risk Management in Journal of Pharmacoepidemiology and Risk Management
- Vol. 14 (2) , 149-157
Real-world Data-based Adverse Drug Reactions Analysis of Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Minoh Ko, PharmD, MS, BCOP, Jieun Choi, PharmD, Sujin Kim, PharmD, Sung Hwan Kim, MS, Eun Jung Cho, BPharm, Yoon Sook Cho, PhD, Young Il Koh, MD, PhD and Jung Mi Oh, PharmD. Journal of Pharmacoepidemiology and Risk Management 2022;14:149-57. https://doi.org/10.56142/jperm.22.0014
- 30 September 2022
- Published by Korean Society for Pharmacoepidemiology and Risk Management in Journal of Pharmacoepidemiology and Risk Management
- Vol. 14 (2) , 149-157
Open AccessReal-world Data-based Adverse Drug Reactions Analysis of Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Minoh Ko, PharmD, MS, BCOP, Jieun Choi, PharmD, Sujin Kim, PharmD, Sung Hwan Kim, MS, Eun Jung Cho, BPharm, Yoon Sook Cho, PhD, Young Il Koh, MD, PhD and Jung Mi Oh, PharmD. Journal of Pharmacoepidemiology and Risk Management 2022;14:149-57. https://doi.org/10.56142/jperm.22.0014